Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	710 people 2 RCTs in this analysis	Mean difference in endpoint score (Positive and Negative Syndrome Scale [PANSS] total score) with quetiapine (dose range 200–800 mg/day) with ziprasidone (dose range 40–160 mg/day) Absolute results not reported	Mean difference –0.11 95% CI –6.36 to +6.14		Not significant
Systematic review	198 people Data from 1 RCT	Mean difference in endpoint score (PANSS positive symptom subscore) medium term with quetiapine (dose range 200–800 mg/day) with ziprasidone (dose range 40–160 mg/day) Absolute results not reported	Mean difference 0.00 95% CI –2.18 to +2.18		Not significant
Systematic review	198 people Data from 1 RCT	Mean difference in endpoint score (PANSS negative symptom subscore) medium term with quetiapine (dose range 200–800 mg/day) with ziprasidone (dose range 40–160 mg/day) Absolute results not reported	Mean difference +1.60 95% CI –0.34 to +3.54		Not significant